Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana

29 Mar 2013

• By Lisa LaMotta

Related Content

Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance

07 Jan 2013

Use Of Pre-Approval CV Data From Ongoing Trial Gets Once-Over At Canagliflozin Panel

21 Jan 2013

2013 Diabetes NMEs Span Classes, But Safety Is A Review Issue For All

28 Jan 2013

Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission

24 Oct 2012

Related Companies

Johnson & Johnson

Johnson & Johnson

Eli Lilly and Company

Boehringer Ingelheim GmbH

Additional Topics

United States Regulation Approvals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.